Asosiy kontentga oʻtish
Sharh maqola

Roadmap: helium ion therapy

Andrea MairaniNational Center for Radiation Research in Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, GermanyStewart MeinNational Center for Radiation Research in Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, GermanyEleanor A. BlakelyBiological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA, United States of AmericaJürgen DebusGerman Cancer Consortium (DKTK) Core-Center Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, GermanyMarco DuranteTechnische Universität Darmstadt, Institut für Physik Kondensierter Materie, Darmstadt, GermanyA. FerrariHeidelberger Institut für RadioonkologieH. FuchsMedAustron Ion Therapy Center, Wiener Neustadt, AustriaDietmar GeorgMedAustron Ion Therapy Center, Wiener Neustadt, AustriaDavid R. GrosshansThe University of Texas MD Anderson cancer Center, Houston, Texas, United States of AmericaFada GuanThe University of Texas MD Anderson cancer Center, Houston, Texas, United States of AmericaThomas HabererHeidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, GermanySemi HarrabiNational Center for Tumor Diseases (NCT), Heidelberg University Hospital, 69120 Heidelberg, GermanyFelix HorstGSI Helmholtzzentrum für Schwerionenforschung, D-64291 Darmstadt, GermanyTaku InaniwaDepartment of Accelerator and Medical Physics, Institute for Quantum Medical Science, QST, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, JapanChristian P. KargerDepartment of Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, GermanyRadhe MohanThe University of Texas MD Anderson cancer Center, Houston, Texas, United States of AmericaHarald PaganettiDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, United States of AmericaKatia ParodiLudwig-Maximilians-Universität München, Department of Experimental Physics-Medical Physics, Munich, GermanyP. SalaLudwig-Maximilians-Universität München, Department of Experimental Physics-Medical Physics, Munich, GermanyChristoph SchuyGSI Helmholtzzentrum für Schwerionenforschung, D-64291 Darmstadt, GermanyThomas TessonnierHeidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, GermanyU TittThe University of Texas MD Anderson cancer Center, Houston, Texas, United States of AmericaUlrich WeberGSI Helmholtzzentrum für Schwerionenforschung, D-64291 Darmstadt, Germany
2022en
ABI

Annotatsiya

Abstract Helium ion beam therapy for the treatment of cancer was one of several developed and studied particle treatments in the 1950s, leading to clinical trials beginning in 1975 at the Lawrence Berkeley National Laboratory. The trial shutdown was followed by decades of research and clinical silence on the topic while proton and carbon ion therapy made debuts at research facilities and academic hospitals worldwide. The lack of progression in understanding the principle facets of helium ion beam therapy in terms of physics, biological and clinical findings persists today, mainly attributable to its highly limited availability. Despite this major setback, there is an increasing focus on evaluating and establishing clinical and research programs using helium ion beams, with both therapy and imaging initiatives to supplement the clinical palette of radiotherapy in the treatment of aggressive disease and sensitive clinical cases. Moreover, due its intermediate physical and radio-biological properties between proton and carbon ion beams, helium ions may provide a streamlined economic steppingstone towards an era of widespread use of different particle species in light and heavy ion therapy. With respect to the clinical proton beams, helium ions exhibit superior physical properties such as reduced lateral scattering and range straggling with higher relative biological effectiveness (RBE) and dose-weighted linear energy transfer (LET d ) ranging from ∼4 keV μ m −1 to ∼40 keV μ m −1 . In the frame of heavy ion therapy using carbon, oxygen or neon ions, where LET d increases beyond 100 keV μ m −1 , helium ions exhibit similar physical attributes such as a sharp lateral penumbra, however, with reduced radio-biological uncertainties and without potentially spoiling dose distributions due to excess fragmentation of heavier ion beams, particularly for higher penetration depths. This roadmap presents an overview of the current state-of-the-art and future directions of helium ion therapy: understanding physics and improving modeling, understanding biology and improving modeling, imaging techniques using helium ions and refining and establishing clinical approaches and aims from learned experience with protons. These topics are organized and presented into three main sections, outlining current and future tasks in establishing clinical and research programs using helium ion beams—A. Physics B. Biological and C. Clinical Perspectives.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba